Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma
- Jingjing Guo
- Saixia Wang
- Yujing Han
- Zhongyuan Jia
- Runchao Wang
Affiliations: Interventional Department of Liver Diseases, Qingdao Sixth People's Hospital, Qingdao, Shandong 266000, P.R. China, Integrated Outpatient Department, Qingdao Sixth People's Hospital, Qingdao, Shandong 266000, P.R. China, Integrated Traditional Chinese Medicine and Western Medicine Department, Qingdao Sixth People's Hospital, Qingdao, Shandong 266000, P.R. China, Department of General Practice, Jinan Maternity and Child Care Hospital Affiliated to Shandong First Medical University, Jinan Maternity and Child Care Hospital, Jinan, Shandong 250000, P.R. China
- Published online on: May 24, 2021 https://doi.org/10.3892/ol.2021.12815
Copyright: © Guo
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The present study aimed to investigate the effects of transarterial chemoembolization (TACE) on the immune function of patients with hepatocellular carcinoma (HCC). A total of 114 patients with HCC were selected and their peripheral blood was collected before and 1 month after TACE treatment. Flow cytometry and reverse transcription‑quantitative PCR were performed to analyze the changes in immune function in patients before and after treatment. Kaplan‑Meier curves were plotted for survival analysis. The programmed cell death ligand 1 (PD‑L1) and programmed cell death protein 1 (PD1) expression before TACE treatment were significantly higher in patients with poor TACE response compared with those patients with well response. Higher PD‑L1 mRNA expression in the peripheral blood mononuclear cells after TACE predicted a superior prognosis. After TACE treatment, the proportion of CD4+/CD8+ cells were decreased while the expression levels of programmed cell death protein 1 (PD1) were significantly increased. To conclude, TACE could reduce the proportion of CD4+/CD8+ cells and improve the mRNA expression levels of PD1 in patients with HCC. The expression levels of PD1 and PD‑L1 were closely related to the therapeutic effect of TACE and the prognosis of patients with HCC. TACE combined with immunotherapy may have potential clinical value for patients with HCC.